Black Rock Inc. Crinetics Pharmaceuticals, Inc. Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
A detailed history of Black Rock Inc. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 6,230,371 shares of CRNX stock, worth $177 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
6,230,371
Previous 5,436,104
14.61%
Holding current value
$177 Million
Previous $254 Million
9.67%
% of portfolio
0.01%
Previous 0.01%
Shares
13 transactions
Others Institutions Holding CRNX
# of Institutions
232Shares Held
90MCall Options Held
59.7KPut Options Held
14.8K-
Vanguard Group Inc Valley Forge, PA9.26MShares$264 Million0.0% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.4MShares$182 Million1.78% of portfolio
-
Wellington Management Group LLP Boston, MA5.81MShares$165 Million0.03% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.59MShares$159 Million0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA4.65MShares$132 Million0.6% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.53B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...